Incidental Intra-Hepatic Cholangiocarcinoma and Hepatocholangiocarcinoma in Liver Transplantation: A Single-Center Experience

Serra, Valentina; Tarantino, Giuseppe; Guidetti, C.; Aldrovandi, S.; Cuoghi, M.; Olivieri, Tiziana; Assirati, Giacomo; Ruvo, N. De; Magistri, Paolo; Ballarin, Roberto; Benedetto, F. Di

doi:10.1016/j.transproceed.2015.12.044

Cited by 15 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subgroup analysis for those with solitary incidental ICC or cHCC-CC less than 2 cm in diameter, there was no difference in patient survival when compared to the HCC control group. These studies (31,32,(34)(35)(36)(37)(38) were summarized in Table 4. Based on the recent reports as well as our own experience, the indication of LT for preoperatively diagnosed cHCC-CC could be the same with HCC.…”

mentioning

confidence: 99%

Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital

Togashi

Akamastu

Kokudo

2016

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital

Togashi

Akamastu

Kokudo

2016

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

show abstract

“…Sampling error may also contribute to misdiagnosis, especially in the setting of mixed tumors, where the HCC component may be more prominent and the CCA component is missed. Third, patients regardless of whether they are early or advanced CCA based on preoperative imaging have an estimated recurrence of at least 30% . Even in the international multicenter cohort that suggested early CCA as candidates for LT, they reported a recurrence rate of 13%‐20% in the early group .…”

Section: Discussionmentioning

confidence: 98%

“…Third, patients regardless of whether they are early or advanced CCA based on preoperative imaging have an estimated recurrence of at least 30%. (23,(27)(28)(29) Even in the international multicenter cohort that suggested early CCA as candidates for LT, they reported a recurrence rate of 13%-20% in the early group. (19) In today's climate with the critical organ shortage and disparate mortality for patients with cancer Model for End-Stage Liver Disease (MELD) exception points versus patients with cirrhosis with equal natural MELD scores, such a high recurrence rate may be unacceptable.…”

Section: Discussionmentioning

confidence: 99%

Liver transplantation for intrahepatic cholangiocarcinoma

et al. 2018

View full text Add to dashboard Cite

Although hepatocellular carcinoma (HCC) has become a common indication for liver transplantation (LT), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) are historically contraindicated due to their aggressive behavior. On the basis of recent experiences, some groups have proposed a clinical trial investigating the role of LT for patients with early cholangiocarcinoma (CCA), defined as a single lesion ≤ 2 cm. The purpose of this study is to assess the clinicopathologic features and outcomes following LT for patients who were initially diagnosed with HCC and subsequently found to have either ICC or cHCC-CCA on explant. Patients with the diagnosis of primary liver cancer (PLC) after LT from a single center were retrospectively reviewed. Outcomes for patients with early CCA were compared with patients with HCC within Milan criteria (MC). Out of 618 patients transplanted with PLC, 44 patients were found to have CCA on explant. On the basis of preoperative imaging, 12 patients met criteria for early CCA and were compared with 319 patients who had HCC within MC. The 1- and 5-year overall survival for early CCA versus HCC was 63.6% versus 90.0% and 63.6% versus 70.3% (log-rank, P = 0.25), respectively. Overall recurrence was 33.3% for early CCA versus 11% for HCC. On explant the patients with CCA were more likely understaged with higher tumor grade and vascular invasion. In conclusion, patients with CCA present a diagnostic challenge, which often leads to the finding of more aggressive lesions on explant after LT, higher recurrence rates, and worse post-LT survival. Careful consideration of this diagnostic conundrum needs to be made before a clinical trial is undertaken. Liver Transplantation 24 634-644 2018 AASLD.

show abstract

“…The combination of histological, radiological and biological criteria is important to identify cHCC-ICC patients. Even in patients with cirrhosis and liver tumor with typical enhancement patterns of HCC, biopsies should be advocated in the presence of biological or imaging features suggesting a cHCC-ICC, as the prognosis and the management of these tumors could be different[ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor

Salimon¹,

Chapelle²,

Matysiak‐Budnik³

et al. 2018

WJG

View full text Add to dashboard Cite

Hepatocholangiocarcinoma (cHCC-ICC) is a rare primary hepatic tumor defined by the presence of histological features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Its prevalence ranges from 1%-5% of all primary liver cancers. We report the case of a 55-year-old cirrhotic male patient admitted to our university hospital for dysphagia, revealing a 10 cm lower-third esophageal metastasis of an unresectable cHCC-ICC with stem-cell features. Computed tomography and abdominal magnetic resonance imaging scans revealed multiple hepatic lesions combining features of both HCC and ICC, associated with synchronous bone metastasis. Histological and immunohistochemical analyses of biopsies from the esophageal lesion and the hepatic tumor confirmed the diagnosis of cHCC-ICC with a stem cell-subtype, according to the World Health Organization classification. After a multidisciplinary meeting, the patient was treated with chemotherapy. He received two cycles of a gemcitabine plus cisplatin regimen before bone progression, and he died 3 mo after the initial diagnosis.

show abstract

Incidental Intra-Hepatic Cholangiocarcinoma and Hepatocholangiocarcinoma in Liver Transplantation: A Single-Center Experience

Cited by 15 publications

References 21 publications

Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital

Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital

Liver transplantation for intrahepatic cholangiocarcinoma

Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor

Contact Info

Product

Resources

About